Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers
NCT07009184Phase 1Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [111In]In-DOTA-TCO-trastuzumab in HER2-positive solid tumor (HER2+), sponsored by Radboud University Medical Center. Primary endpoint: Frequency and severity of Adverse Events at 14 days. Started Apr 2026; status: recruiting.
02
Drugs
[111In]In-DOTA-TCO-trastuzumab
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT07009184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07009184.